Teleflex completes 102-patient study enrollment for Teleflex stock

Published on 10/15/2026 at 12:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BIOMAG-LL enrollment ended with 102 patients on October 12, 2026. Teleflex stock costs EUR 110.30 on October 15, 2026, with Q2 revenue at USD 570.33 million.

Clinical study enrollment advances

Teleflex completed BIOMAG-LL enrollment with 102 patients on October 12, 2026.
Second-quarter revenue reached USD 570.33 million, while adjusted revenue growth was 4.7 percent.
Teleflex stock was trading at EUR 110.30 at 12:33 p.m. CEST at Lang & Schwarz on October 15, 2026.

Isometrische 3D-Grafik der Wertschöpfungskette von Rohstoff bis Krankenhauslieferung — Teleflex Inc. (US8793691069) dargestellt als isometrisches 3D-Diagramm der gesamten Wertschöpfungskette medizinischer Produkte weltweit, Illustration mit AI erstellt.

Teleflex Inc. (ISIN US8793691069) was trading at EUR 110.30 at Lang & Schwarz on October 15, 2026 at 12:33 p.m. CEST. The company had completed enrollment in its BIOMAG-LL clinical study with 102 patients across 14 European centers on October 12, 2026, according to Teleflex.

What does 102-patient enrollment add?

The study evaluates 35 mm and 40 mm Freesolve resorbable magnesium scaffolds for newly diagnosed coronary lesions up to 38 mm. Its primary endpoint is target lesion failure after 12 months, with follow-up scheduled at 1, 6, 12, 36 and 60 months. The longer scaffold sizes are also part of the ongoing BIOMAG-III pivotal trial.

The enrollment milestone expands the clinical evidence base for Teleflex's interventional cardiology portfolio, but it does not yet provide an efficacy result. For investors, the distinction matters because enrollment is an operating milestone rather than a revenue contribution.

Q2 guidance still sets the frame

Teleflex reported second-quarter revenue of USD 570.33 million, up 28.9 percent on a GAAP year-over-year basis, while adjusted earnings per share reached USD 1.76. Adjusted pro forma constant-currency growth was 4.7 percent and the adjusted operating margin was 19.6 percent, according to Benzinga.

Management lowered its 2026 pro forma adjusted constant-currency revenue-growth outlook to 3.5 percent to 4.5 percent from 4.5 percent to 5.5 percent. At the same time, adjusted earnings-per-share guidance increased to USD 6.90 to USD 7.20 from USD 6.25 to USD 6.55. The combination points to a sharper earnings focus while integration work continues.

Stock valuation and operating milestones

Teleflex had a market capitalization of USD 5.2 billion and a 52-week primary-exchange range of USD 100.18 to USD 145.00 as of October 14, 2026. Its primary listing is on the New York Stock Exchange under ticker TFX. The company operates in medical technology, with products spanning anesthesia, emergency medicine, interventional cardiology and radiology, interventional urology and military medicine.

The current investment debate therefore links a concrete clinical milestone with a more demanding operating target. BIOMAG-LL supplies a measurable development step, while the 2026 outlook leaves revenue execution and integration progress as the nearer financial tests.

Teleflex stock remains tied to execution

The BIOMAG-LL enrollment milestone strengthens the development pipeline, while the second-quarter guidance reset keeps the operating outlook central to the stock story.

Teleflex stock was trading at EUR 110.30 at Lang & Schwarz on October 15, 2026 at 12:33 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Teleflex stock.